UzbekistanTuberculosis profile
Population  2016 31 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 1.9 (1.8–1.9) 5.9 (5.9–5.9)
Mortality (HIV+TB only) 0.35 (0.23–0.49) 1.1 (0.74–1.5)
Incidence  (includes HIV+TB) 24 (17–32) 76 (53–103)
Incidence (HIV+TB only) 1.2 (0.8–1.7) 3.8 (2.5–5.3)
Incidence (MDR/RR-TB)** 10 (7.6–13) 32 (24–40)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 1.2 (0.82–1.6) 8.9 (6–12) 10 (6.8–14)
Males 1.4 (0.93–1.9) 12 (8.3–16) 14 (9.2–18)
Total 2.6 (1.8–3.5) 21 (14–28) 24 (17–32)
TB case notifications, 2016  
Total cases notified 18 441
Total new and relapse 16 050
          - % tested with rapid diagnostics at time of diagnosis 76%
          - % with known HIV status 100%
          - % pulmonary 67%
          - % bacteriologically confirmed among pulmonary 45%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 67% (49–96)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.1 (0.07–0.13)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 758 4%
          - on antiretroviral therapy 496 65%
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  4 700
(4 000–5 400)
Estimated % of TB cases with MDR/RR-TB 24% (18–30) 63% (50–75)  
% notified tested for rifampicin resistance 87% 52% 14 639
MDR/RR-TB cases tested for resistance to second-line drugs   1 365
Laboratory-confirmed cases MDR/RR-TB: 1 956, XDR-TB: 184
Patients started on treatment **** MDR/RR-TB: 1 986, XDR-TB: 184
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 89% 15 220
Previously treated cases, excluding relapse, registered in 2015 82% 2 617
HIV-positive TB cases registered in 2015    
MDR/RR-TB cases started on second-line treatment in 2014 62% 3 602
XDR-TB cases started on second-line treatment in 2014    
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment 100%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
86% (79–94)
TB financing, 2017  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-11-20 Data: www.who.int/tb/data